TACTILE SYSTEMS TECHNOLOGY INC (TCMD) Form 8-K — Nov 2, 2026
Tactile Medical reported Q3 2026 revenue of $91.9 million, up 7% year-over-year, driven by 13% growth in its core lymphedema business — its fifth consecutive quarter of double-digit growth — while gross margin expanded to 77%. However, net income fell to $7.2 million ($0.31 diluted EPS) from $8.2 million ($0.36) a year ago, as operating expenses grew 13% to $60.9 million on growth investments and airway clearance revenue dropped 25% amid the AffloVest inventory transition.
Key figures
- Eps
- 0.31
- Revenue
- 91900000
- Guidance
- FY2026 revenue $360-366M (~9-11% growth); Adjusted EBITDA raised to $50-52M from $49-51M
- Net Income
- 7200000
- Total Assets
- 291294000
- Cash Position
- 75100000
- Shares Outstanding
- 22495939
- Buyback q3
- $6.2M repurchased; $12.5M remaining under $25.0M program
- Opex growth
- 13% to $60.9M
- Gross margin
- 77% vs 76% in Q3 2025
- Adjusted ebitda 9m
- $29.5M vs $21.8M
- Adjusted ebitda q3
- $14.3M vs $14.4M in Q3 2025
- Lymphedema revenue growth
- 13% to $81.8M
- Airway clearance revenue change
- -25% to $10.0M
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.